Predicine, a precision medicine company based in Silicon Valley, announced today that the company has entered into a global strategic partnership with Suzhou Kintor Pharmaceuticals to increase the speed and efficiency of biomarker-driven global clinical trials for Kintor’s novel oncology drugs and the development of companion diagnostics for FDA and CFDA approvals. Kintor will leverage...
Hayward, Calif., April. 30, 2018 — Predicine today announced a 600-gene liquid biopsy panel, PredicineATLAS, to help drug companies accelerate clinical trials and the development of targeted cancer drugs and immunotherapies. The panel is expected to be one of the industry’s largest liquid biopsy panels, covering gene content of major commercially available TMB panels in...
Predicine, a Hayward, Calif.-based precision medicine company, today announced it has completed its $13.5M Series A financing from Sangel Capital, Rongsheng Investment, and Highlight Capital. Predicine provides an integrated oncology biomarker solution that includes an innovative RNA+DNA liquid biopsy test and a one-stop biomarker and data analysis platform to support targeted cancer therapeutics and global clinical...
For almost every cancer, immune infiltrates are prognostic markers for better overall outcome,” says Bernard A. Fox, Ph.D., CEO of UbiVac and Harder Chair for Cancer Research, Earle A. Chiles Research Institute. Predictive biomarkers are indicators of whether a patient should get a specific therapy. The use of such biomarkers has been given various names,...
